Delivery Order SPE2DB22D1017-SPE2DB26FYPDM
- Not listed
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $8,155.21 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. The contract, awarded on September 22, 2025, with an ultimate completion date of September 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $11,794.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This competitively awarded contract, with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $19,218.06 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This is a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.93 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. The contract was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and employs firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB26FYPDMDelivery Order
The Defense Logistics Agency awarded a $2,287.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector units. The contract, which carries an ultimate completion date of October 17, 2025, represents a non-set-aside competitive award with performance to be executed at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems through its extensive portfolio of pharmaceutical and medical supply deliveries. The company's award history demonstrates consistent performance on competitively awarded contracts with the Defense Logistics Agency across multiple therapeutic domains. Actemra (tocilizumab) is a biologic immunosuppressant used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in supplying specialized medical therapies to support military healthcare programs. This delivery order exemplifies the operational flexibility of the DLA Troop Support Medical prime vendor vehicle in fulfilling specific pharmaceutical requirements for federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 10/16/25 |